First AD

Second AD

Martin Dietrich, MD, PhD, is a medical oncologist with The US Oncology Network Cancer Care Centers of Brevard and an assistant professor of internal medicine at the University of Central Florida College of Medicine in Orlando, Florida.

Mike J. Pishvaian, MD, PhD, is director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs and an associate professor of oncology at Johns Hopkins Medicine in Baltimore, Maryland.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

Mechanisms of KRAS(ON) Inhibitors

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

How the Mechanisms of KRAS(ON) Inhibitors Differ From KRAS(OFF) Inhibitors